Copyright Reports & Markets. All rights reserved.

Global Tardive Dyskinesia (TD) Treatment Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Valbenazine
      • 1.4.3 Deutetrabenazine
    • 1.5 Market by Application
      • 1.5.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Share by Application (2019-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Tardive Dyskinesia (TD) Treatment Drugs Market Size
    • 2.2 Tardive Dyskinesia (TD) Treatment Drugs Growth Trends by Regions
      • 2.2.1 Tardive Dyskinesia (TD) Treatment Drugs Market Size by Regions (2019-2025)
      • 2.2.2 Tardive Dyskinesia (TD) Treatment Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Tardive Dyskinesia (TD) Treatment Drugs Market Size by by Players
      • 3.1.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Tardive Dyskinesia (TD) Treatment Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players Head office and Area Served
    • 3.3 Key Players Tardive Dyskinesia (TD) Treatment Drugs Product/Solution/Service
    • 3.4 Date of Enter into Tardive Dyskinesia (TD) Treatment Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type (2014-2019)
    • 4.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 5.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in North America
    • 5.3 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 5.4 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 6.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in Europe
    • 6.3 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 6.4 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    7 China

    • 7.1 China Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 7.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in China
    • 7.3 China Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 7.4 China Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 8.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in Japan
    • 8.3 Japan Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 8.4 Japan Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 9.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 9.4 Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    10 India

    • 10.1 India Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 10.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in India
    • 10.3 India Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 10.4 India Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market Size (2014-2019)
    • 11.2 Tardive Dyskinesia (TD) Treatment Drugs Key Players in Central & South America
    • 11.3 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type
    • 11.4 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 Neurocrine Biosciences, Inc.
      • 12.1.1 Neurocrine Biosciences, Inc. Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.1.4 Neurocrine Biosciences, Inc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019))
      • 12.1.5 Neurocrine Biosciences, Inc. Recent Development
    • 12.2 Teva Pharmaceutical Industries
      • 12.2.1 Teva Pharmaceutical Industries Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.2.4 Teva Pharmaceutical Industries Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.2.5 Teva Pharmaceutical Industries Recent Development
    • 12.3 Pfizer Inc.
      • 12.3.1 Pfizer Inc. Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.3.4 Pfizer Inc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.3.5 Pfizer Inc. Recent Development
    • 12.4 Biogen
      • 12.4.1 Biogen Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.4.4 Biogen Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.4.5 Biogen Recent Development
    • 12.5 Novartis AG
      • 12.5.1 Novartis AG Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.5.4 Novartis AG Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.5.5 Novartis AG Recent Development
    • 12.6 AstraZeneca
      • 12.6.1 AstraZeneca Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.6.4 AstraZeneca Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.6.5 AstraZeneca Recent Development
    • 12.7 GlaxoSmithKline plc.
      • 12.7.1 GlaxoSmithKline plc. Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.7.4 GlaxoSmithKline plc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.7.5 GlaxoSmithKline plc. Recent Development
    • 12.8 Bayer AG
      • 12.8.1 Bayer AG Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.8.4 Bayer AG Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.8.5 Bayer AG Recent Development
    • 12.9 Sanofi
      • 12.9.1 Sanofi Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Tardive Dyskinesia (TD) Treatment Drugs Introduction
      • 12.9.4 Sanofi Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2014-2019)
      • 12.9.5 Sanofi Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions. The treatment of tardive dyskinesia is directly affect the neurological system of the respective patients. This disorder may commonly occurs in smoker than non-smoker, and also in the patient of depression, anxiety disorder and others.
      In 2018, the global Tardive Dyskinesia (TD) Treatment Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Tardive Dyskinesia (TD) Treatment Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Tardive Dyskinesia (TD) Treatment Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Neurocrine Biosciences, Inc.
      Teva Pharmaceutical Industries
      Pfizer Inc.
      Biogen
      Novartis AG
      AstraZeneca
      GlaxoSmithKline plc.
      Bayer AG
      Sanofi

      Market segment by Type, the product can be split into
      Valbenazine
      Deutetrabenazine

      Market segment by Application, split into
      Hospitals
      Clinic
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Tardive Dyskinesia (TD) Treatment Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Tardive Dyskinesia (TD) Treatment Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Tardive Dyskinesia (TD) Treatment Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now